Showing results (1-10 of 490) with videos related to
Sort By:
Pageof 49
Journal of Cardiovascular Pharmacology|May 8, 2020
PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized TherapyChase Board, Michael S Kelly, Michael D Shapiro, et al.Current Cardiology Reports|March 27, 2023
With Current Safety and Efficacy Data, Should Statins Be Made Available as Nonprescription Over-the-Counter Drugs?Anurag Mehta, Dave L Dixon, Anum Saeed, et al.Journal of Cardiovascular Pharmacology|July 6, 2026
Olezarsen and Plozasiran: Novel apoC-III targeting medications for the treatment of hypertriglyceridemiaMichael S Kelly, Jelena Lewis, Dylan Zuch, et al.Journal of Clinical Lipidology|July 4, 2017
Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg/dL)Michael S Kelly, Craig Beavers, John D Bucheit, et al.Journal of Clinical Lipidology|June 4, 2025
Evaluation of lipid-lowering therapy in patients with elevated lipoprotein(a) levelsMichael S Kelly, Ruth N Jeminiwa, Fatima Gohar, et al.Pharmacotherapy|February 6, 2016
Effectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic ReviewDave L Dixon, Steven P Dunn, Michael S Kelly, et al.The American Journal of Medicine|April 4, 2020
Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular RiskDave L DixonThe American Journal of Managed Care|December 9, 2022
The impact of PCSK9 modulation on cardiovascular outcomes: recent advances and the managed care implicationsDave L DixonCardiovascular Diabetology|May 30, 2019
The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitusSalvatore Carbone, Dave L DixonJournal of Pharmacy Practice|October 6, 2017
Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With GoutEmily Huneycutt, Chase Board, Jennifer N ClementsPageof 49